Metropolis Healthcare announced a robust 23% year-on-year revenue growth at the consolidated level for Q2 FY26 (July-September 2025). This growth was driven by strong performance in preventive health check-ups and wellness offerings. The company’s diversified portfolio and strategic acquisitions contributed to its resilience against seasonal headwinds. Metropolis is debt-free with a net cash surplus of approximately INR 55 crores.
Q2 FY26 Performance Highlights
Metropolis Healthcare has reported strong financial results for the second quarter of fiscal year 2026, showcasing significant growth and strategic advancements. Key highlights include:
- Revenue Growth: Approximately 23% year-on-year increase, including revenues from Core Diagnostics, Scientific Pathology, and other acquired entities.
Segment Performance
Specific segments within Metropolis Healthcare demonstrated notable growth:
- TruHealth Wellness: Recorded year-on-year growth of approximately 25%.
- Specialty Segments: Experienced year-on-year growth of approximately 36%.
Core Diagnostics and Acquisitions
The company’s strategic initiatives in diagnostics and pathology have yielded positive results:
- Core Diagnostics: Improved from a breakeven position in Q4 FY25 to a high single-digit margin in Q2 FY26, driven by operational efficiencies and synergies.
- Recent Acquisition: The acquisition of Dr. RS Patil’s Ambika Pathology Laboratory, Kolhapur, effective September 18, 2025, strengthens Metropolis’s leadership position in the Kolhapur region.
B2C and B2B Revenue
- B2C Revenue: Registered a year-on-year growth of around 16%.
- B2B Revenue: Grew by approximately 34%, driven by higher contributions from Core Diagnostics.
Financial Position
Metropolis Healthcare maintains a strong financial footing:
- Debt-Free Status: The company is debt-free on a consolidated basis.
- Cash Surplus: Has a net cash surplus of approximately INR 55 crores.
Standalone Performance
- Revenue Growth: Grew by approximately 12% year-on-year, driven by increased patient and test volumes, a favorable shift in product mix, and improved realizations.
- EBITDA Margins: Demonstrated quarter-on-quarter improvement, reflecting resilient business operations and strong operating leverage. Margins also showed a positive year-on-year trend.
Source: BSE
